Business Wire

Medicalbit Foundation Co., Ltd. To Make ASCA Tokens Public

Del

The Medicalbit Foundation, which is currently undergoing an initial virtual currency coin offering (ICO) in Estonia, has decided to make its ASCA tokens publicly available as the first step in the Asclepius Network project.

The goal of Asclepius Network is to make leading-edge medical treatment available to all peoples of the world, and Japan has been chosen for the first location in Asia to expand business.
The project’s mission is to accumulate the world’s cutting-edge medical treatment knowledge and medical records within a blockchain system. This would form a mechanism that would enable anyone in the world to receive the benefits of leading-edge medical treatments anywhere in the world. To further that end, the project is forming a network of leading-edge medical researchers from Japan, as well as from Europe and the United States.
In practical terms, the project is engaged in the development of next-generation electronic medical records as well as the development of smart device apps to gather existing medical records. At this point, the project has already been approved for six patents in Japan.
Plans call for the establishment of blood and cancer screening facilities in 2019, using state of the art technologies from Japan, in conjunction with major diagnostic centers that are already involved in health screenings for millions of persons annually within China, as well as with the major hospital groups that manage dozens of hospitals within China.
In addition, proof-of-concept testing has already begun for a service to deliver Japanese pharmaceuticals to patients suffering from chronic illnesses.
This effort within China is initially estimated, based on preliminary calculations made with project partners, to reach an annual scope ranging from several tens of billions of yen to several hundreds of billions of yen.

Furthermore, a monetary fund has been established to allow participation within the sustainable development goals project set forth by the United Nations as a means to realize the project’s ideal of offering the benefits of leading-edge medical treatment to the peoples of the world. Plans call for the fund to be used predominantly for fields that include the free provision of treatment to areas of the world currently beyond the reach of such treatment.

Participation in the Asclepius Network project for these efforts will require ASCA tokens, and the project seeks investors and business partners interested in bringing leading-edge medical treatment to all the peoples of the world.

Description of Offering: Thursday, March 21st, 10:00 AM JST
Offering Trader: TopForce
URL: www.top-force.com/

Moving forward, plans call for global development based on joint work with partners in the countries of Asia, including Singapore, Malaysia, and India, following a model similar to that used for China. There will also be incremental increases to the number of offering traders from April of 2019 onward.

ICO Implementation Company: MEDICALBIT FOUNDATION OÜ
Harju maakond, Tallinn, Kesklinna linnaosa, Narva mnt 5, 10117

MBC URL: https://www.medicalbit.ee/
ASCA URL: https://www.asclepius.network/
Project Management Company: Japan Medical Solutions Co., Ltd.
9F Nihonbashi Ningyocho Ishii Building, 3-1-17 Ningyo-cho Nihonbashi, Chiyoda Ward, Tokyo
JPM URL: http://www.jpmedsn.com/

Contact information

Inquiries:
Medicalbit Foundation
Hiroo Uchiyama
info@medicalbit.io

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 15:55:00 CETPressemelding

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 14:29:00 CETPressemelding

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of

Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 14:15:00 CETPressemelding

Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha

Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation22.3.2019 13:00:00 CETPressemelding

Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190322005013/en/ Trueman Man Clinic Network has been successfully completed the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation). The SWITCH Premature Ejaculation Surgery (SWITCH operation) developed in 2010 by Dr. Yang, the chief director of the Trueman Man Clinic Network, can reduce the side effects of penile neurectomy and maintain the stable reduction of the glans sensation. The Trueman Man Clinic Network is the leading hospitals for male enhancement surgeries in Korea consists of 11 clinics, with 16 doctors working. As of 2019, more than 43,000 man clinic surgeries have been performed. (Photo: Business Wire) The Trueman Man Clinic Network is the leading hospitals for m

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible22.3.2019 11:22:00 CETPressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX®▼ (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). “Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical Affairs, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “We are incredibly grateful to the patients and investigators who participated in the MAIA clinical trial programme and look forward to working closely with the regulatory authorities to secure approval of this new combination.” The submission is supported by data from the Phase 3 MAIA (MMY3008) study, which were presented at the 60th Annual Meeting of the American

Bartek Ingredients Expands Leadership Team21.3.2019 22:35:00 CETPressemelding

Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa